Adrenomed AG. (8/13/19). "Press Release: Adrenomed AG Takes Part in Four Upcoming Conferences". Hennigsdorf.

	Organisation	Adrenomed AG
	Organisation 2	University of Nijmegen (Radboud University)
	Product	adrecizumab
	Product 2	Sachs Annual Biotech in Europe Forum 2019 Basel
	Person	Hein, Frauke (Deutsche Biotech Innovativ 201211 Managing Director of MLDx GmbH + Adrenomed)
	Person 2	von Hummel, Julia (MC Services 201811)

Adrenomed AG, the vascular integrity company, announced today its participation at four upcoming conferences in Europe. Adrenomed representatives will be available for networking and one-to-one meetings at the following events:

Weimar Sepsis Update – Symposium

September 11th – 13th, 2019, Congress Centrum Neue Weimarhalle, Weimar, Germany
Adrenomed will co-host the lunch symposium “Beyond Standard of Care – New Perspectives on Vascular Integrity in Shock” on September 13th, 12:00 – 13:30 CET.
https://www.sepsis-gesellschaft.de/kongress/

19th Annual Biotech in Europe Forum (Sachs Conference)

September 25th – 26th, 2019, Congress Center Basel, Switzerland
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will participate in the “Platform Technologies & Novel Therapeutics Panel” on September 25th, 10:45 CET.
https://www.sachsforum.com/bef19-about.html

European Business Development Conference (EBDC)

September 25th – 26th, 2019, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will give a “Spotlight Talk on Sepsis” on September 26th, 12:00 CET.
https://www.biodeutschland.org/de/european-business-development-conference-2019.html

32nd European Society of Intensive Care Medicine (ESICM) LIVES

September 28th – October 2nd, 2019, CityCube, Berlin, Germany
Prof. Dr. Peter Pickkers, Radboud University, Department of Intensive Care, Nijmegen, The Netherlands, will give a presentation about “Adrenomedullin in sepsis, effect of the non-inhibitory antibody Adrecizumab”, session “Innovation in sepsis treatment”, on October 1st, 16:20 CET, room Stockholm.
https://www.esicm.org/events/32nd-annual-congress-berlin/

About Adrenomed

Adrenomed AG is a German privately-financed, clinical stage biopharmaceutical company. Adrenomed´s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate Adrecizumab is a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials. www.adrenomed.com

Adrenomed AG
@adrenomed

Contact

Adrenomed AG
Frauke Hein, Ph.D. (Chief Business Officer)
phone: +49 (0)3302 2077814
fhein@adrenomed.com

Media Inquiries
MC Services AG
Eva Bauer/Julia von Hummel
phone: +49 (0)89 21022880
adrenomed@mc-services.eu

Record changed: 2021-01-05